Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ERA 25: Switching from sMRAs to Finerenone
Author(s): Beatriz Fernandez Fernandez Added: 1 month ago
ERA 2025 - Real-world outcomes show switching from treatment with steroidal mineralocorticoid receptor antagonists (sMRAs) to finerenone is a safe option in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).Dr Beatriz Fernandez Fernandez (Hospital Universitario Fundación Jiménez Dïaz, Madrid, ES) joins us to discuss real-world outcomes from a study investigating the effect of… View more

Cardiovascular Renal Metabolic
ESC 24: FINE-HEART: Finerenone in HF & CKD
Author(s): Muthiah Vaduganathan Added: 10 months ago
ESC Congress 2024 — Finerenone improved outcomes in two trials in patients with CKD with T2D, and in patients with HFmrEF and HFpEF.Investigator, Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, US) joins us in London to discuss the findings from the FINE-HEART pooled analysis (Bayer).FINE-HEART is a pre-specified, exploratory pooled analysis combining data from three phase III clinical… View more

Heart Failure

Prevention & Chronic Conditions
ESC 24: MRAs in Heart Failure
Author(s): Added: 10 months ago
ESC Congress 2024 — MRAs reduce the risk of cardiovascular events in patients with HF, HFpEF and HFrEF.Prof Pardeep Jhund (University of Glasgow, UK) joins us to discuss findings from a study investigating mineralocorticoid receptor antagonists (MRAs) across different types of heart failure.This pre-specified, patient-level meta-analysis of RALES (spironolactone), EMPHASIS-HF (eplerenone), TOPCAT… View more

Heart Failure
Bridging the Gap in Cardio-Renal Care
Author(s): Paola Fioretto , Rajiv Agarwal Added: 1 month ago
Filmed on location at ERA 2025 in Vienna, Austria, this three-part video series brings together internationally recognised experts Prof Rajiv Agarwal (Indiana University School of Medicine, Indianapolis, US) and Prof Paola Fioretto (University of Padova, Padova, IT) for an insightful peer-to-peer discussion on the latest advances in chronic kidney disease (CKD) and cardio-renal management… View more

Cardiovascular Renal Metabolic

Guidelines & Statements
Spironolactone versus Eplerenone for Resistant Hypertension
Author(s): Hanselim Lim , Wuri Noviar Hamdani Added: 1 year ago

Prevention & Chronic Conditions
Decoding the Future of HF — Key Takeaways from 2024
Author(s): Muthiah Vaduganathan , Orly Vardeny , Added: 7 months ago
Recorded at American Heart Association 2024 in Chicago, Dr Muthiah Vaduganathan (Brigham and Women’s Hospital and Harvard Medical School, Boston, US), Dr Orly Vardeny (University of Minnesota Medical School, Minneapolis, US) and Prof Pardeep Jhund (University of Glasgow, Glasgow, UK) explore cardiometabolic disease in heart failure with mid-range or preserved ejection fraction (HFmrEF and HFpEF)… View more

Heart Failure
Gaps in the Heart Failure Ecosystem
Author(s): Weiqin Lin , David Sim , Lim Choon Pin , et al Added: 1 year ago

Imaging & Diagnostics

Heart Failure
Hyperkalaemia in Acute Heart Failure: An Asian Population Study
Author(s): Wy Jin Quah , Maizatu Akma Sulong , Ghazali Ahmad , et al Added: 2 weeks ago

Cardiovascular Renal Metabolic
Implementation of Guidelines in Heart Failure: Why it Needs Improving
Author(s): Michel Komajda Added: 1 year ago

Guidelines & Statements

Heart Failure
HFA 24: FINE-HEART: Design & Baseline Characteristics
Author(s): Muthiah Vaduganathan Added: 1 year ago
HFA 24 - We are joined by Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, US) to discuss the design and baseline characteristics of the FINE-HEART(Bayer) integrated pooled analysis of finerenone, an on-steroidal mineralocorticoid receptor (MRA) antagonist, in over 19000 patients with heart failure and CKD.FINE-HEART includes patients with type 2 diabetes, chronic kidney disease and/or… View more

Heart Failure

Prevention & Chronic Conditions